RECOMBINANT VACCINE MARKET ANALYSIS –
Recombinant vaccines are created by employing recombinant DNA technology or genetic engineering to combat deadly diseases in humans and animals. A recombinant vaccine is a biological preparation that induces active acquired immunity to a specific disease. People who are vaccinated create antibodies against the protein antigen, which protects them from contracting the disease when they are attacked by infectious microorganisms. These vaccinations work by stimulating the immune system in order to prevent diseases caused by numerous viruses and bacteria. In the treatment of diseases such as human papillomavirus, typhoid, and malaria, these vaccines are far more refined and effective than traditional vaccines. Furthermore, due to highly structured livestock and high demand for livestock products in Europe, Europe dominates the animal recombinant vaccines market as compared to other regions.
To Get Research PDF Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/455
According to the World Health Organization, around 18 million people died as a result of an absence of availability to care for their disease. According to the WHO Report 2017, immunization can prevent 2 million – 3 million fatalities in the U.S. each year, with 1.5 million fatalities easily prevented. There were around 19.5 million infants who did not receive a basic vaccination. Technology is always evolving, resulting in the development of more effective vaccinations for disease, and companies are attempting to produce new vaccines for illnesses such as cancer, the Zika virus, and others.
The global recombinant vaccine market was worth US$ 830.2 million in 2016 and is expected to grow at a 6.0 % CAGR over the forecast period 2017 and 2025.
Increased prevalence of zoonotic diseases and innovative technologies are expected to drive the global recombinant vaccines market growth over the forecast period.
There is a steady rise in diseases caused by viruses or bacteria, such as HPV, malaria, swine flu, and others, which has increased the demand for vaccines and resulted in the elimination of diseases such as tetanus and polio in some countries. With the advancement of technology, there has been an improvement in vaccines that are more effective than standard vaccines and have no adverse effects. These vaccines are simple to inject intravenously, intramuscularly, or intradermally. In 2015, there were around 212 million cases of malaria and 429,000 deaths reported due to malaria in the U.S. According to the Centers for Disease Control and Prevention’s 2017 report, around 49.9 % of children of age 6 months to 17 years got an influenza vaccine in the U.S.
Christmas Sale is Live!!!!
Buy now and Get 25-30% of Discount on This Report
Buy-Now this Research Report – https://www.coherentmarketinsights.com/insight/buy-now/455
Increasing R&D investment for the discovery of modern vaccines, as well as greater awareness and pet adoption, are expected to support the demand for recombinant vaccines.
Several market players are working on the production of vaccines for various diseases that have affected humans in a short period of time, such as H1N1 flu, Ebola, and Zika virus. The companies are also working on the production of cancer vaccines. Different types of cancer, such as breast cancer, brain cancer, prostate cancer, blood cancer, kidney cancer, skin cancer, lung cancer, bladder cancer, and solid tumors cancer are the target areas for recombinant vaccine development, which is expected to boost the global recombinant vaccine market growth during the forecast period. According to the World Cancer Research Fund International, around 1.7 million new breast cancer cases were reported worldwide in 2012. Breast cancer is being targeted in active NCI-sponsored cancer prevention or treatment clinical studies involving vaccinations. The vaccination therapy, with or without trastuzumab, is being tested in phase II clinical trials for patients with stage IV breast cancer. Phase II trial of the folate receptor alpha peptide vaccination with GM-CSF in patients with triple-negative breast cancer. According to the National Cancer Institute, around 1,685,210 new cancer cases were diagnosed in the U.S. in 2016, with 595,690 individuals dying from cancer. According to the American Society for the Prevention of Cruelty to Animals, around 3.2 million shelter animals are adopted in the U. S. every year (1.6 million cats and 1.6 million dogs), and pet adoption is expected to rise, increasing the demand for recombinant vaccines for animals in the coming years.
Major players operating in the global recombinant vaccines market are Sanofi S A, Protein Science Corporation, Bharat Biotech, GlaxoSmithKline Plc., Pfizer Inc., Novartis AG, Merck & Co. Inc., Green Cross Corporation, and Bayer AG.
To Get more Business Statergies Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/455
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Product Type
- Market Snippet By Disease Type
- Market Snippet By End User
- Market Snippet By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Industry Trend
- Epidemiology/Prevalence/Incidence
- Merger and Acquisitions
- New Product Type Approvals/Launch
- Promotion and Marketing Initiatives
- Market Dynamics
- Global Recombinant Vaccines Market, By Product Type, 2015 – 2025 (USD Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, 2015 – 2025
- Segment Trends
- Subunit Recombinant Vaccines
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Attenuated Recombinant Vaccines
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Vector Recombinant Vaccines
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Introduction
- Global Recombinant Vaccines Market, By Disease Type, 2015 – 2025 (USD Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, 2015 – 2025
- Segment Trends
- Infectious Disease
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, 2015 – 2025
- Cancer
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Allergy
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Introduction
- Global Recombinant Vaccines Market, By End User, 2015 – 2025 (USD Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-O-Y Growth Analysis, 2015 – 2025
- Segment Trends
- Recombinant Human Vaccines
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Animal Recombinant Vaccines
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Poultry
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Companion Animal Vaccines
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Livestock
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Porcine
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Aquaculture Vaccines
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2015 – 2025, (USD Million)
- Poultry
- Introduction
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837